A Phase 2 interventional study of Eculizumab in Antibody Mediated Rejection, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 41 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-03.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization therapy.
The main objective of this study was to evaluate the safety and efficacy of eculizumab to prevent AMR in sensitized recipients of living donor kidney transplants requiring desensitization therapy prior to transplantation. The primary endpoint focused on acute AMR during the first 9 weeks post-transplantation.
Patients were to be vaccinated against N. meningitidis at least 14 days prior to study drug initiation and revaccinated 30 days later. If not vaccinated 14 days prior, prophylactic antibiotics were to be administered. Pre-transplant infectious disease assessment was to be performed as part of the screening assessment.
Patients were to undergo desensitization therapy according to the practice of the local transplant center prior to transplantation, and this desensitization practice was to be uniformly applied for all patients at that center throughout the study. The actual length of desensitization for an individual patient was based on the clinical judgment of the Transplant Center team. Rituximab was prohibited in all patients as part of the pre-transplantation desensitization therapy due to potential pharmacodynamic interactions.
The control group was designed to test eculizumab against the best available care (referred to as standard of care, or SOC) consisting of plasmapheresis (PP) and/or intravenous immunoglobulin (IVIg). The best available care consisting of PP and IVIg was chosen because these modalities combined represented the most prevalent therapy reported in the literature and were the best available therapies at the time of this protocol's inception as per the transplant community.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
Drug: Eculizumab
Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
Also known as: Soliris
Treatment Failure Rate
The primary efficacy variable was a binary outcome variable where patients meeting the composite endpoint of the occurrence of 1) biopsy-proven acute AMR, 2) graft loss, 3) patient death, or 4) loss to follow-up definition at Week 9 post-transplantation were considered treatment failures and all others were considered treatment successes.
Time frame: 9 weeks post-transplantation
Recruitment period lasted from Nov 2011 to Mar 2014. Forty-one sites in Australia, the European Union, and North America participated in this study.
| Milestone | Eculizumab | Standard of Care |
|---|---|---|
| Started | 51 | 51 |
| Completed | 48 | 49 |
| Not completed | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Transplantectomy | 0 | 1 |
The primary efficacy variable was a binary outcome variable where patients meeting the composite endpoint of the occurrence of 1) biopsy-proven acute AMR, 2) graft loss, 3) patient death, or 4) loss to follow-up definition at Week 9 post-transplantation were considered treatment failures and all others were considered treatment successes.
| Participants | Eculizumab | Standard of Care |
|---|---|---|
| Treatment Failure Rate | 5 | 7 |
Collected over Adverse events were collected throughout the 3-year study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 1/51 (2%) | 43/51 (84.3%) | 51/51 (100%) |
| Standard of Care | 1/51 (2%) | 48/51 (94.1%) | 51/51 (100%) |
| Event | Eculizumab | Standard of Care |
|---|---|---|
| Kidney transplant rejectionImmune system disorders | 22/51 | 28/51 |
| DiarrhoeaGastrointestinal disorders | 3/51 | 8/51 |
| Urinary tract infectionInfections and infestations | 2/51 | 7/51 |
| Escherichia urinary tract infectionInfections and infestations | 4/51 | 6/51 |
| LymphoceleVascular disorders | 3/51 | 5/51 |
| GastroenteritisInfections and infestations | 0/51 | 4/51 |
| PneumoniaInfections and infestations | 3/51 | 4/51 |
| PyelonephritisInfections and infestations | 4/51 | 2/51 |
| UrosepsisInfections and infestations | 4/51 | 2/51 |
| BronchitisInfections and infestations | 2/51 | 3/51 |
| Event | Eculizumab | Standard of Care |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 16/51 | 28/51 |
| Urinary tract infectionInfections and infestations | 28/51 | 18/51 |
| DiarrhoeaGastrointestinal disorders | 22/51 | 27/51 |
| NauseaGastrointestinal disorders | 26/51 | 19/51 |
| LeukopeniaBlood and lymphatic system disorders | 16/51 | 23/51 |
| Oedema peripheralGeneral disorders | 15/51 | 21/51 |
| Kidney transplant rejectionImmune system disorders | 19/51 | 17/51 |
| PyrexiaGeneral disorders | 12/51 | 16/51 |
| HyperglycaemiaMetabolism and nutrition disorders | 14/51 | 16/51 |
| HypophosphataemiaMetabolism and nutrition disorders | 16/51 | 12/51 |
| Age, Customized(Participants) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn - gestational age < 37 wk | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 47 | 49 | 96 |
| From 65 to 84 years | 4 | 2 | 6 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| Female | 37 | 30 | 67 |
| Male | 14 | 21 | 35 |
| Race (NIH/OMB)(Participants) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 12 |
| White | 37 | 36 | 73 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Region of Enrollment(Participants) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| Australia | 4 | 1 | 5 |
| France | 3 | 7 | 10 |
| Germany | 1 | 1 | 2 |
| Italy | 2 | 4 | 6 |
| Netherlands | 0 | 3 | 3 |
| Norway | 1 | 1 | 2 |
| Spain | 3 | 4 | 7 |
| Sweden | 1 | 4 | 5 |
| United Kingdom | 10 | 5 | 15 |
| United States | 26 | 21 | 47 |
| Total Donor-Specific Antibodies (DSA)(mean fluorescence intensity (MFI)) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| Mean | 15394.7 ± 14163.78 | 17469.8 ± 12573.44 | 16411.1 ± 13380.16 |
| Highest Single Donor-Specific Antibodies (DSA)(mean fluorescence intensity (MFI)) | Eculizumab | Standard of Care (SOC) | Total |
|---|---|---|---|
| Mean | 8135 ± 4048.08 | 8740.7 ± 4289.97 | 8431.7 ± 4157.87 |
Plan to share: No
Ran from Nov 2011 to primary completion in May 2014, 30 months.
Results were first posted in Apr 2017, 2 years 11 months after primary completion. A results delay was requested in Nov 2016.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →